Effects of cardiovascular medications on primary patency of hemodialysis arteriovenous fistula.

Scientific Reports
Te-I ChangChung-Te Liu

Abstract

While the patency of vascular access is essential for hemodialysis patients, optimal pharmaceutical treatment to maintain arteriovenous fistula (AVF) patency remains lacking. As cardiovascular diseases are highly prevalent in patients with end-stage renal disease, various cardiovascular medications have also been used to maintain AVF patency. However, previous studies revealed inconsistent therapeutic effects and a comprehensive evaluation of this issue is needed. The present retrospective, longitudinal cohort study included patients receiving successful AVF creation. The evaluated cardiovascular medications included antiplatelet agents, antihypertensive agents, nitrates and nitrites, statins, dipyridamole, and pentoxifylline. The outcome was AVF primary patency. All laboratory data and medication profiles were recorded at baseline and followed at 3-month interval, until the end of the 2-year study period. Cox proportional regression model with time-dependent covariates was used to evaluate the risk for AVF patency loss. A total of 349 patients were included in the present study, in which 57% were men and the mean age was 65 ± 14 years. Among the included patients, 40% used antiplatelet agents, 27% used dipyridamole and 36% use...Continue Reading

References

Jan 1, 1985·Scandinavian Journal of Urology and Nephrology·K C GröntoftR Olander
Oct 9, 1998·Scandinavian Journal of Urology and Nephrology·K C GröntoftJ P Dickinson
Sep 29, 2001·Kidney International·R K DhingraF K Port
Mar 6, 2002·Journal of Vascular Surgery·Anton N SidawyK Craig Kent
Dec 3, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Rajiv SaranUNKNOWN Dialysis Outcomes and Practice Patterns Study
Oct 26, 2005·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Cathie Sudlow
Dec 16, 2006·Basic & Clinical Pharmacology & Toxicology·Sergey B ZhuplatovAlfred K Cheung
Feb 3, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Atul SajgureDevasmita Choudhury
Oct 24, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Prabir Roy-ChaudhuryRino Munda
Feb 8, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Henricus J T HuijbregtsUNKNOWN CIMINO study group
May 15, 2008·JAMA : the Journal of the American Medical Association·Laura M DemberUNKNOWN Dialysis Access Consortium Study Group
Nov 1, 2008·Annals of Vascular Surgery·Marco RighettiAdalberto Tommasi
May 22, 2009·The New England Journal of Medicine·Bradley S DixonUNKNOWN DAC Study Group
Sep 13, 2011·Seminars in Dialysis·Timmy LeeUNKNOWN North American Vascular Access Consortium
Apr 27, 2012·Annals of Vascular Surgery·Marcus FokouFru Angwafo
Jul 3, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Michael AllonSilvio Litovsky
Feb 24, 2016·Scientific Reports·Hao-Hsiang ChangChih-Cheng Hsu
Mar 26, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Marwan TabbaraRoberto I Vazquez-Padron
Oct 30, 2016·The Journal of Vascular Access·Laisel MartinezLoay H Salman
Jan 6, 2017·JAMA Internal Medicine·Ashley B IrishUNKNOWN Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Grou
Jul 16, 2017·Journal of the American Society of Nephrology : JASN·Alfred K CheungUNKNOWN Hemodialysis Fistula Maturation Study Group
Jan 4, 2018·Journal of the American Society of Nephrology : JASN·Laisel MartinezRoberto I Vazquez-Padron
Aug 3, 2018·American Journal of Nephrology·Ke WangUNKNOWN the Hemodialysis Fistula Maturation Study Group
Nov 20, 2018·Journal of Cellular and Molecular Medicine·Qiong YanYoshihisa Fujikura
Mar 4, 2019·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Laisel MartinezRoberto I Vazquez-Padron

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
percutaneous transluminal angioplasty

Software Mentioned

Sigma Plot
SAS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
Tushar J VachharajaniJonathan J Taliercio
© 2021 Meta ULC. All rights reserved